Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo.

Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.
- EligibilityCriteria: Inclusion Criteria:  Chronic Inflammatory Pain of greater than 3 months duration and greater than or equal to 5/10 intensity that has not responded to other conservative therapies such as rest, ice, compression or other oral medications.  Exclusion Criteria:  Severe allergy to any specific food component such as nut, egg or soy - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult